[The highly effective biological preparation biosporin].
In this paper, information is given about a new original probiotic, biosporin, worked out at the D. K. Zabolotnyĭ Institute of Microbiology and Virology of the Academy of Sciences of the Ukraine. The preparation consists of two strains of aerobic sporiferous bacteria Bacillus subtilis and Bacillus licheniformis characterized by mutually complementary spectrum of antagonistic activity with respect to a broad range of pathogenic and conventionally pathogenic microorganisms. The mechanism of treatment and prophylactic action of biosporin was established to be of original, multifactorial and many-sided character. Along with its high antagonistic activity, ability to stimulate non-specific resistance of the macroorganism, biosporin is endowed with enzymatic properties owing to which the preparation regulates and stimulates digestion and has also a pronounced antiallergenic effect. The data obtained from the preclinical studies of the preparation in a great number of animals (including primates) were entirely supported by the results of the state clinic trials of biosporin carried out at the clinics of Kiev, Dnepropetrovsk, Moscow. Parameters characterizing microflora were found to have returned to normal in all the patients with acute intestinal infections, dysbacterioses of different etiology, non-specific ulcerative colitis (more than 800 patients having been kept under observation) during the course of treatment with biosporin, with no instance reported of deterioration in general condition or emergence of any adverse reaction. The clinical application of the preparation being permitted, the Chemicals and Pharmaceuticals Plant of Dnepropetrovsk has started producing it.
V V
VV
Smyrnov
S R
SR
Reznyk
I V
IV
Sorokulova
D000284:Administration, Oral; D000818:Animals; D000898:Antibiosis; D001407:Bacillus; D001412:Bacillus subtilis; D001424:Bacterial Infections / Q000276:immunology / Q000382:microbiology / Q000628:therapy; D001685:Biological Factors / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007410:Intestinal Diseases / Q000276:immunology / Q000382:microbiology / Q000628:therapy
D001685:Biological Factors; C091592:biosporin
Vysokoefektivnyĭ biolohichnyĭ preparat biosporyn.